Raleigh, North Carolina | April 13, 2026
Endpoint Clinical has announced the release of Elosity® R3, a major upgrade to its next-generation Randomization and Trial Supply Management (RTSM) platform, designed to address the growing complexity of modern clinical trials. The latest release introduces advanced clinical supply management capabilities, enhanced data transparency, and integrated AI-driven insights, enabling sponsors and contract research organizations (CROs) to optimize trial execution with greater precision and efficiency. As clinical trials become increasingly global and adaptive, Elosity R3 positions itself as a comprehensive digital solution that enhances operational visibility, compliance, and decision-making across the trial lifecycle.
Enhanced RTSM Capabilities Improve Clinical Trial Efficiency
Elosity R3 introduces a wide range of enhancements aimed at improving clinical supply chain operations and study execution. Key features include central pharmacy management, flexible sourcing strategies, and patient rollover capabilities across studies, allowing trial sponsors to manage complex, multi-phase studies more effectively. Additionally, the platform offers portfolio-level supply optimization tools, enabling organizations to better allocate resources across multiple trials while minimizing waste and delays.
These capabilities are critical in today’s clinical environment, where adaptive trial designs and global study footprints require highly coordinated and scalable systems. By improving study configuration, audit readiness, and global access management, Elosity R3 supports regulatory compliance and operational consistency, aligning with Good Clinical Practice (GCP) standards.
AI-Powered eloAI Transforms Data Insights and Decision-Making
Advertisement
A standout feature of Elosity R3 is the expansion of eloAI, the platform’s built-in artificial intelligence engine, which allows clinical teams to interact with trial data using natural language queries. This innovation enables users to quickly generate real-time insights, visualizations, and operational analytics, significantly reducing the time required to analyze complex datasets. By integrating AI directly into the RTSM platform, Endpoint Clinical empowers teams to move from data collection to actionable insights faster, improving responsiveness and decision-making. Importantly, the system maintains study blinding, role-based access controls, and regulatory compliance, ensuring that data integrity and confidentiality are preserved. This combination of AI-driven intelligence and compliance-focused design represents a major advancement in clinical trial technology.
Cloud-Based Architecture Enables Scalable and Integrated Trials
Built on a cloud-based, integration-first architecture, Elosity R3 provides seamless connectivity across clinical and enterprise systems, enabling end-to-end visibility throughout the trial lifecycle. This architecture supports real-time data sharing, interoperability, and scalability, which are essential for managing large, multi-site clinical trials. The platform’s ability to integrate with external systems ensures that sponsors and CROs can maintain a unified operational view, reducing silos and improving collaboration. As trials continue to evolve toward more data-driven and decentralized models, platforms like Elosity R3 play a critical role in enabling efficient, compliant, and adaptive trial execution.
Driving Innovation in Clinical Trial Technology
The release of Elosity R3 reflects broader industry trends toward digital transformation and AI integration in clinical research. With increasing pressure to reduce trial timelines and improve outcomes, organizations are adopting advanced technologies to enhance operational efficiency, data accuracy, and regulatory compliance. Endpoint Clinical’s focus on combining RTSM functionality with AI-powered analytics positions Elosity R3 as a next-generation solution capable of addressing these challenges. By providing tools that improve visibility, governance, and adaptability, the platform supports the successful execution of complex clinical trials in a rapidly evolving healthcare landscape.
The launch of Elosity R3 marks a significant milestone in the advancement of clinical trial management technology, offering a powerful combination of AI-driven insights, robust RTSM capabilities, and scalable cloud infrastructure. As clinical trials become more complex and data-intensive, solutions like Elosity R3 will be essential in enabling faster, more efficient, and compliant trial execution. Endpoint Clinical’s latest innovation underscores the growing importance of technology-driven transformation in clinical research, paving the way for improved outcomes and accelerated drug development.
Source: Endpoint Clinical press release
